Efficacy of individualised starting dose (isd) and fixed starting dose (fsd) of niraparib per investigator assessment (ia) in newly diagnosed advanced ovarian cancer (oc) patients

Baurain, J.F. (J. F.); Braicu, E.I. (Elena Ioana); Follana, P. (Philippe); González-Martín, A. (Antonio); Graybill, W. (Whitney); Gupta, D. (Dyvia); Monk, B.J. (Bradley J.); Omalley, D. (David); Peen, U. (Ulla); Prendergast, E. (Emily)

Efficacy of individualised starting dose (isd) and fixed starting dose (fsd) of niraparib per investigator assessment (ia) in newly diagnosed advanced ovarian cancer (oc) patients

Authors: J.F. (J. F.) Baurain
E.I. (Elena Ioana) Braicu
P. (Philippe) Follana
A. (Antonio) González-Martín
W. (Whitney) Graybill
D. (Dyvia) Gupta
B.J. (Bradley J.) Monk
D. (David) Omalley
U. (Ulla) Peen
E. (Emily) Prendergast
Publication date: 1 January 2020
Publisher: 'BMJ'

Abstract

Niraparib is a poly(ADP-ribose) polymerase inhibitor approved for maintenance treatment of patients with newly diagnosed or recurrent OC that responded to platinumbased chemotherapy and treatment in heavily-pretreated recurrent OC. Here we report efficacy in patients receiving the FSD and ISD in the PRIMA/ENGOT-OV26/GOG-3012 trial (NCT02655016)

Similar works

Full text

Available Versions

Universidad de Navarra

oai:dadun.unav.edu:10171/67945

Last time updated on 27/11/2023